Compare Hewlett Packard Enterprise Co (HPE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hewlett Packard Enterprise Co vs TransMedics Group Inc — how do they compare? Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Hewlett Packard Enterprise Co is far larger — about 34.4× TransMedics Group Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and TransMedics Group Inc for 24 Days on average.
| HPE | TMDX | |
|---|---|---|
Market Cap | $94.25B | $2.74B |
Volume | 16,060,854 | 949,331 |
Sector | Technology | Health |
52-Week High | $73.46 | $150.42 |
52-Week Low | $20.01 | $61.99 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $108.28B | $3.13B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPE's stock trades at $70.99, down 1.56% today but near its 52-week high, with a bullish technical outlook and strong AI-driven momentum. Recent earnings beats and a $1.2B AI server order from Vultr highlight robust demand. Valuation metrics show a P/E of 36.6 and P/S of 2.4, while cash flow trends indicate volatility with a net outflow of $9.25B in 2025 but a projected rebound in 2026.
The outlook is positive, driven by AI infrastructure growth and raised guidance, but risks include high debt levels and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting cautious optimism amid near-term overbought conditions.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
